Clinical Trials Logo

Filter by:
NCT ID: NCT03462810 Available - Clinical trials for Infection, Human Immunodeficiency Virus

GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

Start date: n/a
Phase: N/A
Study type: Expanded Access

The goal of this compassionate use program is to provide a mechanism to supply Cabotegravir, CAB on an individual named patient basis for treatment of individuals who have no available treatment alternatives and/or limited treatment options (e.g., who are unable to participate in the Phase III clinical studies or do not qualify), and are in need of new drugs to construct an effective antiviral regimen and may require the use of parenterally administered drug given underlying medical conditions. You can access ViiV's Policy on Compassionate via 17.pdf.

NCT ID: NCT03456076 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Participants With ALK Positive Non-Small Cell Lung Cancer

Start date: June 18, 2018
Phase: Phase 3
Study type: Interventional

This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months. Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.

NCT ID: NCT03446352 Enrolling by invitation - Fallers Clinical Trials

Multimodal Exercise Programs for Falls Prevention: A Randomized Controlled Trial

Start date: March 5, 2018
Phase: N/A
Study type: Interventional

The aim of present study is to analyze and compare the effect of two exercise programs - psychomotor exercise program vs exercise combined program (psychomotor + whole body vibration) - on risk factors for falls and falls occurrence of community-dwelling older adults who are fallers or are "at high risk of falling". This experimental study is a randomized controlled trial. The program will run for 16 weeks (3 sessions / week of 75 minutes), followed by 8 weeks of follow-up without intervention. Participants will be assessed 1) at baseline, 2) at the end of the program, and 3) after the follow-up. Participants will be randomly allocated to three groups: experimental group 1 (psychomotor program); experimental group 2 (combined program) and control group.

NCT ID: NCT03445000 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Treatment of Pretreated RET-rearranged Advanced NSCLC

Start date: March 2018
Phase: Phase 2
Study type: Interventional

A research study to evaluate the activity of alectinib for the Treatment of pretreated patients with advanced NSCLC that have confirmed RETrearrangement.

NCT ID: NCT03443973 Not yet recruiting - Alzheimer's Disease Clinical Trials

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Start date: July 31, 2018
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with prodromal to mild AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

NCT ID: NCT03435393 Recruiting - Brugada Syndrome Clinical Trials

Ripple Mapping for Epicardial Mapping of Brugada Syndrome

Start date: September 1, 2017
Phase: N/A
Study type: Observational

Whether a mapping algorithm "Ripple-mapping" is able to rapidly identify the areas of long-duration multicomponent electrograms which constitute the targets for ablation for an automated strategy remains to be assessed.

NCT ID: NCT03410693 Not yet recruiting - Clinical trials for Carcinoma, Transitional Cell

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

Start date: July 20, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have received Prior platinum-containing chemotherapy. The primary objective of the entire study is to compare rogaratinib (BAY1163877) with chemotherapy (docetaxel, paclitaxel or vinflunine) in terms of prolonging the Overall survival (OS) of patients with FGFR positive urothelial carcinoma. At randomization, patients will have locally advanced or metastatic urothelial carcinoma and have received at least one prior platinum-containing chemotherapy regimen. Only patients with FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off applied.

NCT ID: NCT03407482 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus

Start date: January 11, 2018
Phase: Phase 2
Study type: Interventional

This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to 48 weeks.

NCT ID: NCT03407027 Enrolling by invitation - Low Back Pain Clinical Trials

Efficacy of Corticoid Infiltration in Quadratus Lumborum Syndrome

Start date: November 1, 2017
Phase: Phase 4
Study type: Interventional

This study has the primary goal of evaluating the efficacy of corticoid infiltration in the quadratus lumborum syndrome, aiming to determine if there are benefits with the use of corticosteroids and if they exist, if this improvement comes only from the systemic effects of corticosteroid administration.

NCT ID: NCT03400150 Recruiting - Prostate Cancer Clinical Trials

ProSpaceā„¢ Balloon System Pivotal Study BP-007

Start date: January 3, 2018
Phase: N/A
Study type: Interventional

The ProSpaceā„¢ System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the ProSpace System to reduce the radiation dose delivered to the anterior rectum. ProSpace is a balloon composed of a biodegradable material that maintains that space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.